

Anne Geneviève Marcelin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9483511/publications.pdf>

Version: 2024-02-01

375
papers

11,472
citations

28274

55
h-index

54911

84
g-index

387
all docs

387
docs citations

387
times ranked

11219
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2022, 74, 707-710.	5.8	10
2	Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2022, 74, 1093-1096.	5.8	57
3	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 24-31.	1.9	57
4	Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2022, 225, 502-509.	4.0	4
5	Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection. <i>Diagnostics</i> , 2022, 12, 104.	2.6	4
6	Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies. <i>Viruses</i> , 2022, 14, 226.	3.3	26
7	Primaquine as a Candidate for HHV-8-Associated Primary Effusion Lymphoma and Kaposi's Sarcoma Treatment. <i>Cancers</i> , 2022, 14, 543.	3.7	1
8	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	1.6	1
9	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma. <i>Cancers</i> , 2022, 14, 986.	3.7	5
10	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. <i>Cells</i> , 2022, 11, 1015.	4.1	7
11	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). <i>Journal of Infection</i> , 2022, 84, e101-e104.	3.3	15
12	A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study. <i>Biomedicines</i> , 2022, 10, 931.	3.2	1
13	Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. <i>Frontiers in Immunology</i> , 2022, 13, 844727.	4.8	2
14	Human Herpesvirus 8 seroprevalence among blood donors in Mali. <i>Journal of Medical Virology</i> , 2022, , .	5.0	0
15	Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5065.	4.1	5
16	Phenotypic Heterogeneity of Fulminant COVID-19-Related Myocarditis in Adults. <i>Journal of the American College of Cardiology</i> , 2022, 80, 299-312.	2.8	20
17	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. <i>Journal of Infection</i> , 2022, 85, e104-e108.	3.3	29
18	SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study. <i>Viruses</i> , 2022, 14, 1529.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1762-e1765.	5.8	93
20	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. <i>Clinical Infectious Diseases</i> , 2021, 73, e4064-e4072.	5.8	38
21	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 307-317.	5.6	131
22	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021, 20, 102729.	5.8	26
23	Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 102, 10-13.	3.3	46
24	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 477-481.	3.0	0
25	In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1695.	4.1	72
26	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. <i>Nature Communications</i> , 2021, 12, 844.	12.8	146
27	Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 311-315.	2.2	0
28	No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1553-1557.	3.0	1
29	Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2235-2241.	2.9	8
30	Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab166.	0.9	8
31	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1893-1897.	3.0	1
32	Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2148-2152.	3.0	3
33	Prevalence of genotypic baseline risk factors for cabotegravir+rilpivirine failure among ARV-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2983-2987.	3.0	14
34	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	2.9	47
35	Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1056-1057.	6.0	13
36	The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, 119-145.	3.3	23

#	ARTICLE	IF	CITATIONS
37	Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. <i>International Journal of Infectious Diseases</i> , 2021, 108, 610-616.	3.3	16
38	Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2400-2406.	3.0	4
39	Seroprevalence and molecular diversity of Human Herpesvirus 8 among people living with HIV in Brazzaville, Congo. <i>Scientific Reports</i> , 2021, 11, 17442.	3.3	4
40	27372 Meclozine, a novel anti-inflammatory therapeutic in <i>C. acnes</i> -induced inflammation in vitro and in vivo. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB138.	1.2	0
41	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, e1-e3.	3.3	146
42	SARS-CoV-2 infection in patients with primary central nervous system lymphoma. <i>Journal of Neurology</i> , 2021, 268, 3072-3080.	3.6	7
43	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Frontiers in Immunology</i> , 2021, 12, 761250.	4.8	7
44	Kaposi's Sarcoma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposi's Sarcoma. <i>Cancers</i> , 2021, 13, 6208.	3.7	12
45	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 170-182.	3.0	50
46	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2435-2438.	5.8	17
47	Long-term follow-up of HIV-infected patients on dolutegravir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 675-680.	3.0	6
48	Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?. <i>Aids</i> , 2020, 34, 167-175.	2.2	25
49	Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106039.	2.5	3
50	Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy. <i>Aids</i> , 2020, 34, 1609-1614.	2.2	5
51	Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. <i>Journal of Clinical Virology</i> , 2020, 130, 104573.	3.1	19
52	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study's authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3699-3700.	3.0	2
53	No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection. <i>Aids</i> , 2020, 34, 1745-1753.	2.2	6
54	Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1733-1735.	3.4	41

#	ARTICLE	IF	CITATIONS
55	Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. <i>Emerging Infectious Diseases</i> , 2020, 26, 1636-1637.	4.3	118
56	Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naïve and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1588-1590.	3.0	29
57	The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris Area. <i>Clinical Infectious Diseases</i> , 2020, 71, e530-e531.	5.8	6
58	M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1290-1293.	3.0	16
59	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1272-1279.	3.0	2
60	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	3.0	20
61	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.0	1
62	Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1 <i>H</i> -pyrazole-5-carboxylate as an HIV-1 replication inhibitor. <i>RSC Medicinal Chemistry</i> , 2020, 11, 577-582.	3.9	8
63	New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. <i>Journal of Infectious Diseases</i> , 2020, 222, 1320-1328.	4.0	14
64	Methods comparison for molecular diagnosis of human herpesvirus 8 infections. <i>Journal of Clinical Virology</i> , 2020, 126, 104308.	3.1	1
65	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , 2019, 93, 50-59.	3.2	3
66	Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2716-2722.	3.0	6
67	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2742-2751.	3.0	26
68	Variability of the HIV-1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3440-3444.	3.0	13
69	Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 145-149.	1.1	3
70	INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz177.	0.9	9
71	Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 513-517.	2.5	0
72	New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2019-2023.	3.0	8

#	ARTICLE	IF	CITATIONS
73	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS 163 ETRAL Study. <i>Pharmacotherapy</i> , 2019, 39, 514-520.	2.6	4
74	Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1368-1375.	3.0	11
75	High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 678-681.	2.5	6
76	HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1679-1692.	3.0	8
77	Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. <i>BMC Infectious Diseases</i> , 2019, 19, 1064.	2.9	25
78	Caution is needed in interpreting HIV transmission chains by ultradeep sequencing. <i>Aids</i> , 2019, 33, 691-699.	2.2	11
79	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 433-438.	1.3	29
80	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 614-617.	3.0	23
81	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 473-479.	3.0	15
82	Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 207-214.	5.8	48
83	Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 80-83.	2.5	8
84	New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. <i>Eurosurveillance</i> , 2019, 24, .	7.0	4
85	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. <i>Antiviral Therapy</i> , 2018, 23, 463-465.	1.0	27
86	Dolutegravir resistance mutations: lessons from monotherapy studies. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 237-245.	3.1	39
87	Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	11
88	Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1158-1166.	3.0	13
89	Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1039-1044.	3.0	40
90	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. <i>Lancet HIV</i> , 2018, 5, e116-e125.	4.7	187

#	ARTICLE	IF	CITATIONS
91	Bridging β -Cyclodextrin Prevents Self-Inclusion, Promotes Supramolecular Polymerization, and Promotes Cooperative Interaction with Nucleic Acids. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 7753-7758.	13.8	46
92	Emerging resistance mutations in PI-naïve patients failing an atazanavir-based regimen (ANRS Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702)	3.0	2
93	Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naïve (TN) patients in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 83-91.	1.4	6
94	No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 173-176.	3.0	13
95	Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification. <i>Retrovirology</i> , 2018, 15, 80.	2.0	22
96	Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. <i>PLoS ONE</i> , 2018, 13, e0198334.	2.5	9
97	Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2141-2146.	3.0	19
98	Reply to Das and Berkhout, "How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir". <i>MBio</i> , 2018, 9, .	4.1	9
99	Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. <i>Clinical Infectious Diseases</i> , 2018, 67, 1883-1889.	5.8	4
100	Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3143-3147.	3.0	9
101	Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2485-2492.	3.0	19
102	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018, 66, 1588-1594.	5.8	15
103	HIV Coreceptor Tropism in Different Reservoirs. , 2018, , 702-705.		0
104	State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap. <i>AIDS Reviews</i> , 2018, 20, 27-42.	1.0	11
105	Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw571.	3.0	3
106	Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. <i>HIV Clinical Trials</i> , 2017, 18, 1-16.	2.0	7
107	iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease. <i>Blood</i> , 2017, 129, 855-865.	1.4	16
108	High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naïve HIV-infected Children in Mali. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e258-e263.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2351-2354.	3.0	7
110	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. <i>Aids</i> , 2017, 31, 1048-1051.	2.2	74
111	HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 630-632.	3.0	2
112	Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. <i>MBio</i> , 2017, 8, .	4.1	71
113	Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. <i>Journal of Clinical Virology</i> , 2017, 96, 49-53.	3.1	27
114	Brief Report: De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 2241-2246.	5.6	12
115	Characterization of a <i>Propionibacterium acnes</i> Surface Protein as a Fibrinogen-Binding Protein. <i>Scientific Reports</i> , 2017, 7, 6428.	3.3	20
116	Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 448-454.	2.1	1
117	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1-10.	1.1	28
118	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3172-3176.	3.0	5
119	TLR-2 Recognizes <i>Propionibacterium acnes</i> CAMP Factor 1 from Highly Inflammatory Strains. <i>PLoS ONE</i> , 2016, 11, e0167237.	2.5	51
120	Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions. <i>British Journal of Dermatology</i> , 2016, 175, 1251-1262.	1.5	14
121	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. <i>Aids</i> , 2016, 30, 327-330.	2.2	27
122	Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, e43-e45.	2.1	2
123	Efficacy of protease inhibitor monotherapy vs triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. <i>HIV Medicine</i> , 2016, 17, 358-367.	2.2	61
124	Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw537.	3.0	16
125	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naïve patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2252-2261.	3.0	7
126	Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2651-2653.	3.0	5

#	ARTICLE	IF	CITATIONS
127	Systematic Review to Determine the Prevalence of Transmitted Drug Resistance Mutations to Rilpivirine in HIV-Infected Treatment-Naive Persons. <i>Antiviral Therapy</i> , 2016, 21, 405-412.	1.0	20
128	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. <i>Aids</i> , 2016, 30, 221-230.	2.2	59
129	Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2248-2251.	3.0	17
130	Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2646-2650.	3.0	45
131	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
132	Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. <i>Clinical Infectious Diseases</i> , 2016, 62, 1297-1303.	5.8	64
133	Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype. <i>Journal of Clinical Virology</i> , 2016, 76, 51-54.	3.1	6
134	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
135	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. <i>Aids</i> , 2015, 29, 853-856.	2.2	5
136	Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. <i>HIV Medicine</i> , 2015, 16, 553-562.	2.2	49
137	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015, 10, e0127816.	2.5	3
138	Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France. <i>PLoS ONE</i> , 2015, 10, e0145885.	2.5	7
139	Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 130-135.	3.0	12
140	Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and $\Delta 32$ heterozygote HIV-1-infected patient was not associated with functional cure. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 317-319.	3.0	1
141	Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1919-1920.	3.0	0
142	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1507-1512.	3.0	52
143	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015, 16, 297-306.	2.2	9
144	Virological failure of patients on maraviroc-based antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1858-64.	3.0	7

#	ARTICLE	IF	CITATIONS
145	Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing: Table 1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1503-1506.	3.0	18
146	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health, 2015, 15, 209.	2.9	32
147	Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. Journal of Antimicrobial Chemotherapy, 2015, 70, 2347-2353.	3.0	16
148	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). Journal of Antimicrobial Chemotherapy, 2015, 70, 3339-3344.	3.0	6
149	Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 2870-2880.	3.0	17
150	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-2012: impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2015, 70, 2084-2089.	3.0	42
151	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1. Journal of Antimicrobial Chemotherapy, 2015, 70, 2418-2420.	3.0	3
152	Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrobial Agents and Chemotherapy, 2015, 59, 4870-4881.	3.2	10
153	Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. Journal of Antimicrobial Chemotherapy, 2015, 70, 3080-3086.	3.0	68
154	Cost-Effectiveness of Dolutegravir/Abacavir/Lamivudine in HIV-1 Treatment Naïve Patients in France. Value in Health, 2015, 18, A587.	0.3	3
155	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV, 2015, 2, e464-e473.	4.7	69
156	G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 739-749.	3.0	26
157	Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. AIDS Research and Human Retroviruses, 2015, 31, 475-478.	1.1	2
158	Antiretroviral-naïve and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. Journal of Antimicrobial Chemotherapy, 2015, 70, 566-572.	3.0	8
159	HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice. PLoS ONE, 2015, 10, e0138420.	2.5	7
160	HIV Coreceptor Tropism in Different Reservoirs. , 2015, , 1-4.		0
161	Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. Journal of the International AIDS Society, 2014, 17, 19744.	3.0	0
162	Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. Journal of the International AIDS Society, 2014, 17, 19788.	3.0	16

#	ARTICLE	IF	CITATIONS
163	Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2412-2419.	3.0	23
164	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3356-3359.	3.0	2
165	Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. <i>Aids</i> , 2014, 28, 487-491.	2.2	23
166	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1648-1652.	3.0	29
167	High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2531-2535.	3.0	20
168	Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score. <i>Infection</i> , 2014, 42, 295-301.	4.7	1
169	Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naïve patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1086-1089.	3.0	18
170	Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 753-756.	3.0	61
171	New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2118-2122.	3.0	50
172	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. <i>BMC Infectious Diseases</i> , 2014, 14, 122.	2.9	51
173	NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 103-106.	2.2	1
174	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. <i>Journal of Infection</i> , 2014, 69, 408-410.	3.3	2
175	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART. <i>PLoS ONE</i> , 2014, 9, e105853.	2.5	9
176	Transmitted Antiretroviral Drug Resistance in Newly HIV-Infected and Untreated Patients in Ségou and Bamako, Mali. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 182-186.	1.1	12
177	Switching to darunavir/ritonavir 800/100mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. <i>Journal of Medical Virology</i> , 2013, 85, 8-15.	5.0	13
178	Human Herpesvirus 8 (HHV8) Transmission and Related Morbidity in Organ Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 207-213.	4.7	53
179	A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 42-47.	2.5	19
180	Direct Quantification of Cell-Associated HIV DNA in Isolated Rectal and Blood Memory CD4 T Cells Revealed Their Similar and Low Infection Levels in Long-Term Treated HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 255-259.	2.1	9

#	ARTICLE	IF	CITATIONS
181	A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion. <i>Clinical Infectious Diseases</i> , 2013, 57, 745-755.	5.8	15
182	Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2197-8.	3.0	14
183	HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naïve and -experienced patients with different HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 969-972.	3.0	8
184	Pitfalls of HIV genotypic tropism testing after treatment interruption. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 188-189.	3.0	4
185	Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2515-2520.	3.0	4
186	Pulmonary manifestations of human herpesvirus-8 during HIV infection. <i>European Respiratory Journal</i> , 2013, 42, 1105-1118.	6.7	33
187	Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naïve patients infected with B and non-B subtype HIV-1 viruses. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1237-1242.	3.0	42
188	HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 930-935.	3.2	16
189	Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2199-2204.	3.0	7
190	Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2882-2889.	3.0	3
191	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	3.0	41
192	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1400-1405.	3.0	29
193	Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1243-1245.	3.0	18
194	Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes. <i>PLoS ONE</i> , 2013, 8, e54381.	2.5	1
195	Scoring Methods for Building Genotypic Scores: An Application to Didanosine Resistance in a Large Derivation Set. <i>PLoS ONE</i> , 2013, 8, e59014.	2.5	3
196	A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity. <i>PLoS ONE</i> , 2013, 8, e74078.	2.5	10
197	Inflammation and microbial translocation in treatment-controlled HIV patients. <i>Antiviral Therapy</i> , 2013, 18, 837-840.	1.0	0
198	Etravirine Concentrations in the Cervicovaginal Compartment in HIV-1-Infected Women Receiving Etravirine-Containing Antiretroviral Therapy: DIVA 02 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4018-4020.	3.2	10

#	ARTICLE	IF	CITATIONS
199	Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2943-2948.	3.0	33
200	Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-7.	0.7	5
201	Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1470-1474.	3.0	18
202	Coreceptor usage in different reservoirs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 450-455.	3.8	7
203	Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 691-695.	3.0	61
204	Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1475-1478.	3.0	24
205	Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study. <i>HIV Clinical Trials</i> , 2012, 13, 284-288.	2.0	7
206	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. <i>Aids</i> , 2012, 26, 971-975.	2.2	77
207	Circulating Interleukin-6 Levels Correlate with Residual HIV Viraemia and Markers of Immune Dysfunction in Treatment-Controlled HIV-Infected Patients. <i>Antiviral Therapy</i> , 2012, 17, 915-919.	1.0	80
208	Connection Domain Mutations During Antiretroviral Treatment Failure in Mali. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 293-296.	2.1	3
209	E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. <i>Aids</i> , 2012, 26, 1619-1624.	2.2	41
210	The future of integrase inhibitors of HIV-1. <i>Current Opinion in Virology</i> , 2012, 2, 580-587.	5.4	23
211	HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2323-2326.	3.0	44
212	Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm ³ at the time of diagnosis according to HIV-1 coreceptor tropism. <i>Journal of Medical Virology</i> , 2012, 84, 1853-1856.	5.0	7
213	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2487-2493.	3.0	4
214	Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. <i>Journal of Clinical Virology</i> , 2012, 54, 194-196.	3.1	10
215	Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI - ANRS136 Trial over 96 Weeks. <i>PLoS ONE</i> , 2012, 7, e41390.	2.5	28
216	In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. <i>Advances in Virology</i> , 2012, 2012, 1-13.	1.1	6

#	ARTICLE	IF	CITATIONS
217	Risk factors for raltegravir resistance development in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2494-2500.	3.0	10
218	E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations. <i>Antiviral Research</i> , 2012, 93, 167-174.	4.1	6
219	Human herpesvirus 8 transfusion transmission in Ghana, an endemic region of West Africa. <i>Transfusion</i> , 2012, 52, 2294-2299.	1.6	9
220	Multicenter assessment of HIV-1 RNA quantitation in semen in the CREATHE network. <i>Journal of Medical Virology</i> , 2012, 84, 183-187.	5.0	11
221	Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations: Fig. 1. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2700-2702.	3.9	10
222	Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1481-1483.	3.0	18
223	Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. <i>Antiviral Therapy</i> , 2011, 17, 119-123.	1.0	7
224	Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. <i>Aids</i> , 2011, 25, 341-344.	2.2	43
225	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011, 25, 27-36.	2.2	40
226	High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger. <i>Antiviral Therapy</i> , 2011, 16, 429-433.	1.0	23
227	Effect of antiretroviral drugs on the quality of semen. <i>Journal of Medical Virology</i> , 2011, 83, 1391-1394.	5.0	24
228	Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. <i>ChemMedChem</i> , 2011, 6, 2203-2213.	3.2	14
229	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1972-1975.	3.0	14
230	Factors Associated With Virological Failure in HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 1211-1216.	4.0	85
231	Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2831-2836.	3.2	46
232	Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3018-3021.	3.2	32
233	The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2827-2830.	3.0	43
234	Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, e15-e17.	2.1	0

#	ARTICLE	IF	CITATIONS
235	Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. <i>Aids</i> , 2011, 25, 537-539.	2.2	13
236	Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1754-1757.	3.2	10
237	Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 709-712.	3.0	67
238	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. <i>Aids</i> , 2010, 24, 614-617.	2.2	41
239	Patient-Selected Treatment Partners Did Not Protect Against Drug Resistance During First-Line NNRTI-Based HAART in a Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 563-564.	2.1	3
240	Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. <i>Aids</i> , 2010, 24, 2365-2374.	2.2	152
241	Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients*. <i>HIV Medicine</i> , 2010, 11, 666-669.	2.2	6
242	Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir <i>In Vitro</i> and <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 491-501.	3.2	74
243	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2620-2627.	3.0	62
244	Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 118-124.	3.0	49
245	Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 72-77.	3.2	33
246	Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 749-751.	3.0	36
247	Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 50, 773-778.	5.8	377
248	International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1520-1525.	3.2	9
249	Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3335-3340.	3.2	65
250	Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4910-4913.	3.2	23
251	Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 728-733.	3.2	44
252	Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission. <i>PLoS Pathogens</i> , 2010, 6, e1000955.	4.7	141

#	ARTICLE	IF	CITATIONS
253	Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. <i>Aids</i> , 2010, 24, 2887-2889.	2.2	9
254	Resistance to HIV-1 integrase inhibitors: A structural perspective. <i>Drug Resistance Updates</i> , 2010, 13, 139-150.	14.4	68
255	HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. <i>Fertility and Sterility</i> , 2010, 93, 1020-1023.	1.0	32
256	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2305-2318.	3.0	57
257	Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 527-532.	1.5	15
258	Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. <i>Aids</i> , 2010, 24, 2313-2321.	2.2	53
259	HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. <i>Aids</i> , 2010, 24, 2412-2414.	2.2	30
260	Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 795-804.	3.0	91
261	Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1087-1090.	3.0	23
262	Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. <i>Aids</i> , 2009, 23, 95-99.	2.2	15
263	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase) Tj ETQq1 1 0.784314 rgBT /Overlock nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. <i>Aids</i> , 2009, 23, 1605-1608.	2.2	10
264	Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 585-592.	3.0	38
265	Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1543-1545.	3.9	31
266	The Impact of Preexisting or Acquired Kaposi Sarcoma Herpesvirus Infection in Kidney Transplant Recipients on Morbidity and Survival. <i>American Journal of Transplantation</i> , 2009, 9, 2580-2586.	4.7	65
267	HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. <i>Journal of Molecular Recognition</i> , 2009, 22, 480-494.	2.1	17
268	Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. <i>HIV Medicine</i> , 2009, 10, 620-626.	2.2	4
269	Resistance to novel drug classes. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 531-537.	3.8	23
270	Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 60-64.	2.1	37

#	ARTICLE	IF	CITATIONS
271	Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4+ T cells in patients with chronic HIV-1 infection. <i>Aids</i> , 2009, 23, 2265-2275.	2.2	3
272	Characterization and structural analysis of HIV-1 integrase conservation. <i>AIDS Reviews</i> , 2009, 11, 17-29.	1.0	118
273	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. <i>Antiviral Therapy</i> , 2009, 14, 123-9.	1.0	20
274	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. <i>Antiviral Therapy</i> , 2009, 14, 123-129.	1.0	38
275	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. <i>Journal of Medical Virology</i> , 2008, 80, 762-765.	5.0	6
276	Structural effects of amino acid variations between B and CRF02_AG HIV-1 integrases. <i>Journal of Medical Virology</i> , 2008, 80, 754-761.	5.0	20
277	Comparison of two genotypic algorithms to determine HIV-1 tropism. <i>HIV Medicine</i> , 2008, 9, 1-5.	2.2	21
278	Stability of HIV RNA in plasma specimens stored at different temperatures. <i>HIV Medicine</i> , 2008, 9, 790-793.	2.2	17
279	Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit. <i>Journal of Virological Methods</i> , 2008, 149, 285-291.	2.1	24
280	Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 905-908.	3.0	17
281	Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 491-496.	3.2	54
282	Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients. <i>Aids</i> , 2008, 22, 2212-2214.	2.2	24
283	Kaposi's sarcoma in HIV-negative men having sex with men. <i>Aids</i> , 2008, 22, 1163-1168.	2.2	59
284	Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. <i>Aids</i> , 2008, 22, 1677-1679.	2.2	96
285	Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3237-3243.	3.2	45
286	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 451-455.	3.0	6
287	Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4251-4257.	3.2	10
288	The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. <i>Nucleic Acids Research</i> , 2008, 37, 1193-1201.	14.5	128

#	ARTICLE	IF	CITATIONS
289	Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1542-1544.	3.2	14
290	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1362-1368.	3.0	14
291	Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 456-463.	3.0	36
292	The involvement of HIV-1 RNase H in resistance to nucleoside analogues. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 973-975.	3.0	13
293	Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1351-1358.	3.2	256
294	Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. <i>Blood</i> , 2008, 111, 1387-1395.	1.4	43
295	The marriage of science and optimized HIV care in resource-limited settings. <i>Aids</i> , 2008, 22, 2227-2230.	2.2	4
296	Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. <i>Aids</i> , 2007, 21, 1365-1367.	2.2	7
297	Experience of Indinavir/Ritonavir 400/100 mg Twice-Daily Highly Active Antiretroviral Therapy-Containing Regimen in HIV-1-Infected Patients in Bamako, Mali. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 477-479.	2.1	4
298	Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. <i>Aids</i> , 2007, 21, 871-873.	2.2	18
299	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. <i>Journal of Experimental Medicine</i> , 2007, 204, 2473-2485.	8.5	655
300	Relationship between the Quantity of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in Peripheral Blood and Effusion Fluid Samples and KSHV-Associated Disease. <i>Journal of Infectious Diseases</i> , 2007, 196, 1163-1166.	4.0	68
301	Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3067-3074.	3.2	34
302	Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatment-Experienced Patients with HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 392-398.	4.0	14
303	The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient. <i>Aids</i> , 2007, 21, 1492-1494.	2.2	10
304	HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. <i>Aids</i> , 2007, 21, 2341-2343.	2.2	24
305	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. <i>Aids</i> , 2007, 21, 2243-2245.	2.2	27
306	Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients. <i>Journal of Medical Virology</i> , 2007, 79, 207-211.	5.0	22

#	ARTICLE	IF	CITATIONS
307	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. <i>Journal of Infection</i> , 2007, 54, 367-374.	3.3	50
308	Prevalence of HIV-1 Drug Resistance in Treated Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 12-18.	2.1	48
309	Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. <i>Antiviral Therapy</i> , 2007, 12, 247-52.	1.0	6
310	Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. <i>Antiviral Therapy</i> , 2007, 12, 123-9.	1.0	15
311	Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2007, 12, 247-252.	1.0	13
312	Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. <i>Journal of Hepatology</i> , 2006, 44, 62-67.	3.7	89
313	Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. <i>Aids</i> , 2006, 20, 35-40.	2.2	57
314	Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. <i>Aids</i> , 2006, 20, 287-289.	2.2	26
315	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006, 78, 153-160.	5.0	53
316	Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. <i>Journal of Medical Virology</i> , 2006, 78, 877-882.	5.0	41
317	Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2553-2556.	3.2	8
318	Low T Cell Responses to Human Herpesvirus 8 in Patients with AIDS-Related and Classic Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2006, 194, 1078-1088.	4.0	114
319	External Validation of Atazanavir/Ritonavir Genotypic Score in HIV-1 Protease Inhibitor-Experienced Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 127-128.	2.1	5
320	Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine. <i>Antiviral Therapy</i> , 2006, 11, 693-9.	1.0	4
321	Impact of HIV-1 Reverse Transcriptase Polymorphism at Codons 211 and 228 on Virological Response to Didanosine. <i>Antiviral Therapy</i> , 2006, 11, 693-700.	1.0	10
322	Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial. <i>Antiviral Therapy</i> , 2006, 11, 213-222.	1.0	11
323	Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. <i>Aids</i> , 2005, 19, 630-632.	2.2	21
324	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. <i>Aids</i> , 2005, 19, 1239-1240.	2.2	29

#	ARTICLE	IF	CITATIONS
325	Salivary Lactoferrin Is Recognized by the Human Herpesvirus-8. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1249-1258.	0.7	6
326	Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. <i>Journal of Medical Virology</i> , 2005, 76, 297-301.	5.0	17
327	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS) Tj ETQq1 1 0.784314 2 BT /Ov	0.784314	2
328	Clinically Relevant Genotype Interpretation of Resistance to Didanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1739-1744.	3.2	60
329	Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1720-1726.	3.2	52
330	Didanosine in HIV-1 Infected Patients Experiencing Failure of Antiretroviral Therapy: A Randomized Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2005, 191, 840-847.	4.0	53
331	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. <i>European Respiratory Journal</i> , 2005, 26, 969-972.	6.7	46
332	HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2005, 19, 1065-1069.	2.2	31
333	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. <i>Aids</i> , 2005, 19, 25-33.	2.2	56
334	Efficacy of Interferon- γ for the Treatment of Kaposi's Sarcoma Herpesvirus-Associated Uveitis. <i>American Journal of Ophthalmology</i> , 2005, 140, 746-748.	3.3	21
335	Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. <i>Antiviral Therapy</i> , 2005, 10, 479-87.	1.0	8
336	Predictors of virologic response to ritonavir-boosted protease inhibitors. <i>AIDS Reviews</i> , 2005, 7, 225-32.	1.0	5
337	Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study. <i>Antiviral Therapy</i> , 2005, 10, 479-487.	1.0	24
338	Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 644-647.	3.2	16
339	Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4687-4692.	3.2	48
340	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*. <i>HIV Medicine</i> , 2004, 5, 352-359.	2.2	63
341	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. <i>Liver Transplantation</i> , 2004, 10, 295-300.	2.4	65
342	Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. <i>Journal of Medical Virology</i> , 2004, 72, 162-165.	5.0	104

#	ARTICLE	IF	CITATIONS
343	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 16-20.	5.0	22
344	Quantification of Kaposi's Sarcoma-Associated Herpesvirus in Blood, Oral Mucosa, and Saliva in Patients with Kaposi's Sarcoma. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 704-708.	1.1	38
345	Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. <i>Aids</i> , 2004, 18, 1340-1342.	2.2	38
346	Virologic Outcome After Switching From a Nucleoside Reverse Transcriptase Inhibitor to Tenofovir in Patients With Undetectable HIV-1 RNA Plasma Level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 876-878.	2.1	3
347	High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. <i>Haematologica</i> , 2004, 89, 1100-8.	3.5	71
348	Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission. <i>Antiviral Therapy</i> , 2004, 9, 415-421.	1.0	56
349	Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary Sjögren's syndrome using degenerated consensus PCR primers. <i>Journal of Clinical Virology</i> , 2003, 28, 165-168.	3.1	18
350	Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 594-600.	3.2	96
351	Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2713-2715.	3.9	15
352	Rituximab therapy for HIV-associated Castleman disease. <i>Blood</i> , 2003, 102, 2786-2788.	1.4	152
353	Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naïve HIV-infected individuals. <i>Antiviral Therapy</i> , 2003, 8, 603-9.	1.0	6
354	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4³) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). <i>Antiviral Therapy</i> , 2003, 8, 233-237.	1.0	6
355	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naïve HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2003, 8, 603-609.	1.0	17
356	Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1586-1588.	3.2	66
357	Kaposi's Sarcoma Associated with Previous Human Herpesvirus 8 Infection in Heart Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2217-2219.	3.9	27
358	HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. <i>Aids</i> , 2002, 16, 2419-2424.	2.2	45
359	Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2002, 76, 2634-2640.	3.4	91
360	Prospective Study of the Effects of Antiretroviral Therapy on Kaposi Sarcoma-Associated Herpesvirus Infection in Patients With and Without Kaposi Sarcoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 384-390.	2.1	105

#	ARTICLE	IF	CITATIONS
361	Kaposi's sarcoma herpesvirus and HIV-1 seroprevalences in prostitutes in Djibouti. <i>Journal of Medical Virology</i> , 2002, 68, 164-167.	5.0	30
362	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. <i>Antiviral Therapy</i> , 2002, 7, 211-8.	1.0	11
363	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. <i>Antiviral Therapy</i> , 2002, 7, 211-218.	1.0	28
364	HUMAN HERPESVIRUS-8 SEROCONVERSIONS AFTER RENAL TRANSPLANTATION1. <i>Transplantation</i> , 2001, 72, 1319-1320.	1.0	23
365	Clinical Features and Contribution of Virological Findings to the Management of Kaposi Sarcoma in Organ-Allograft Recipients. <i>Archives of Dermatology</i> , 2000, 136, 1452-8.	1.4	66
366	Relationship between Kaposi's sarcoma, Kaposi's sarcoma-associated herpesvirus and AIDS dementia complex. <i>Aids</i> , 2000, 14, 333-335.	2.2	3
367	Primary infection with human herpesvirus 8 in an HIV-1-infected patient. <i>Aids</i> , 2000, 14, 1471-1473.	2.2	4
368	OUTCOME OF KIDNEY TRANSPLANT RECIPIENTS WITH PREVIOUS HUMAN HERPESVIRUS-8 INFECTION1. <i>Transplantation</i> , 2000, 69, 1776-1779.	1.0	91
369	Absence of a link between human herpesvirus 8 and pemphigus. <i>British Journal of Dermatology</i> , 1999, 141, 159-160.	1.5	18
370	Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome. <i>British Journal of Haematology</i> , 1999, 104, 932-933.	2.5	29
371	Human retrovirus-5 and Sjögren's syndrome. <i>Clinical Microbiology and Infection</i> , 1999, 5, 105-106.	6.0	1
372	Lack of evidence of an association between HHV-8 and multiple myeloma. <i>Leukemia</i> , 1998, 12, 1840-1841.	7.2	10
373	Prevalence of Human Herpesvirus 8 Infection Measured by Antibodies to a Latent Nuclear Antigen in Patients With Various Dermatologic Diseases. <i>Archives of Dermatology</i> , 1998, 134, 700-2.	1.4	32
374	HHV-8 and multiple myeloma in France. <i>Lancet</i> , The, 1997, 350, 1144.	13.7	79
375	More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.0	0